Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/joacp.JOACP_562_20 http://scihub22266oqcxt.onion/10.4103/joacp.JOACP_562_20 34759566!8562453!34759566     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Anaesthesiol+Clin+Pharmacol 2021 ; 37 (3): 481-483 Nephropedia Template TP {{tp|p=34759566|t=2021. Intravenous lidocaine infusion in a case of severe COVID-19 infection |pdf=|usr=}}{{34759566}} gab.com Text Intravenous lidocaine infusion in a case of severe COVID-19 infection JO: J Anaesthesiol Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=34759566 #FOAvip A subset of patients with COVID-19 develops a severe inflammatory response that may lead to respiratory and multiorgan failure. Effective treatment strategies to mitigate or interrupt this self-destructive inflammatory process are limited. The local anesthetic lidocaine has anti-inflammatory properties in addition to its analgesic, antiarrhythmic, and sedating effects that may be beneficial in critically ill COVID-19 patients. We report the case of a patient with COVID-19 induced severe respiratory distress who was intubated and received supportive treatment including proning and neuromuscular blockade. He developed a strong inflammatory response that we treated with an intermittent lidocaine infusion resulting in subsequent resolution. This case occurred prior to emerging data from a large dexamethasone use trial that demonstrated a survival benefit from its use in hospitalized COVID-19 patients. At the time, lidocaine was the only anti-inflammatory medication our patient received. Twit Text FOAVip Intravenous lidocaine infusion in a case of severe COVID-19 infection ????J Anaesthesiol Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=34759566 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34759566 #FOAvip English Wikipedia <ref>{{Cite pmid|34759566}}</ref> Intravenous lidocaine infusion in a case of severe COVID-19 infection #MMPMID34759566 Rylova A; Chowdhury S; Amirfarzan H; Leissner KB; Schumann R J Anaesthesiol Clin Pharmacol 2021[Jul]; 37 (3): 481-483 PMID34759566show ga A subset of patients with COVID-19 develops a severe inflammatory response that may lead to respiratory and multiorgan failure. Effective treatment strategies to mitigate or interrupt this self-destructive inflammatory process are limited. The local anesthetic lidocaine has anti-inflammatory properties in addition to its analgesic, antiarrhythmic, and sedating effects that may be beneficial in critically ill COVID-19 patients. We report the case of a patient with COVID-19 induced severe respiratory distress who was intubated and received supportive treatment including proning and neuromuscular blockade. He developed a strong inflammatory response that we treated with an intermittent lidocaine infusion resulting in subsequent resolution. This case occurred prior to emerging data from a large dexamethasone use trial that demonstrated a survival benefit from its use in hospitalized COVID-19 patients. At the time, lidocaine was the only anti-inflammatory medication our patient received. äIntravenous lidocaine infusion in a case of severe COVID-19 infection (epmc).pdf DeepDyve Pubget Overpricing